The purpose of this study is to evaluate the drug-drug-interaction (DDI), pharmacokinetics (PK) and tolerability of HEC74647 combined with HEC110114 in healthy subjects
This is a 2-part study with each part is an open-label study in healthy adult subjects. Total 28 subjects will be enrolled into the study and divided into 2 part (Part A and Part B), 14 subjects in each part. With each part, the subject will be receive study drug per the defined treatment periods of Day 1\~7 and Day 13\~19.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
28
The First Hospital of Jilin University
Changchun, Jilin, China
Adverse Events
Incidence of adverse events
Time frame: From Days 1-26
Cmax
Maximum plasma concentration of study drugs
Time frame: Day 7-12 and Day 19-26
AUC
Maximum plasma concentration of study drugs
Time frame: Day 7-12 and Day 19-26
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.